Business Context and Reporting Period
This Form 8-K is filed by Novelos Therapeutics, Inc. (noted as Cellectar Biosciences, Inc. in metadata) on October 18, 2006. The filing addresses a material accounting error requiring the restatement of audited financial statements for the fiscal year ended December 31, 2005, and unaudited statements for the three and nine-month periods ended September 30, 2005. The error involves the failure to properly account for a deemed non-cash dividend associated with the beneficial conversion feature (BCF) of Series A 8% Cumulative Convertible Preferred Stock issued in late 2005.
Key Financial Metrics and Restatement Impact
The filing does not provide current revenue, cash flow, or liquidity metrics. It focuses exclusively on the revision of Net Loss Attributable to Common Stockholders due to the BCF adjustment. The deemed dividend is non-cash and does not affect the Balance Sheet or Statement of Cash Flows, except for supplemental non-cash disclosures.
| Period | Net Loss (As Reported) | Deemed Dividend Adjustment | Net Loss Attributable to Common (Restated) | EPS (Restated) |
|---|---|---|---|---|
| Quarter Ended Sept 30, 2005 | $(954,872) | $(1,943,377) | $(2,898,249) | $(0.11) |
| Nine Months Ended Sept 30, 2005 | $(2,348,508) | $(1,943,377) | $(4,291,885) | $(0.22) |
| Year Ended Dec 31, 2005 | $(3,053,399) | $(2,141,321) | $(5,194,720) | $(0.24) |
Material Changes Versus Prior Period
The material change is the significant increase in reported Net Loss Attributable to Common Stockholders for all relevant periods. Previously reported EPS figures were understated because the intrinsic value of the BCF was not deducted from net loss. The restatement increases the loss per share for the quarter ended September 30, 2005, from $(0.04) to $(0.11), and for the full year 2005, from $(0.14) to $(0.24).
Management Commentary, Risks, and Unusual Items
Management identified the error during an internal review of previous private placements, specifically regarding the "in-the-money" conversion price of the Preferred Stock. In accordance with EITF No. 98-5 and EITF No. 00-27, the company determined the BCF should have been recorded as a deemed dividend upon issuance. The Audit Committee and independent auditors (Stowe & Degon) concurred with the restatement. The company plans to file amendments to its Form 10-QSB and Form 10-KSB to reflect these corrections. No other risks or unusual items are disclosed in this filing.
Investor Verification Checklist
- Verify the upcoming amended Form 10-KSB and Form 10-QSB filings to confirm the restated financial statements.
- Review the terms of the Series A 8% Cumulative Convertible Preferred Stock to understand the conversion mechanics and BCF valuation.
- Confirm that the restatement does not impact the company's cash position or debt covenants, as the adjustment is non-cash.
- Monitor for any further disclosures regarding the internal review of other securities issuances.